May 13 |
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 7 |
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
|
Apr 24 |
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
|
Mar 27 |
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
|
Mar 16 |
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
|
Mar 13 |
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
|
Mar 13 |
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth
|
Mar 13 |
scPharmaceuticals files for $200M mixed shelf offering
|
Mar 13 |
scPharmaceuticals GAAP EPS of -$0.35 beats by $0.07, revenue of $6.1M beats by $0.33M
|
Mar 13 |
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|